Separately, BidaskClub downgraded CryoPort from a sell rating to a strong sell rating in a research note on Saturday, October 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $24.00.
NASDAQ CYRX opened at $15.10 on Tuesday. The business has a 50 day simple moving average of $14.73 and a 200 day simple moving average of $17.86. CryoPort has a 52-week low of $8.28 and a 52-week high of $25.02. The company has a debt-to-equity ratio of 0.17, a quick ratio of 17.84 and a current ratio of 17.91. The stock has a market cap of $564.54 million, a price-to-earnings ratio of -48.71 and a beta of 0.80.
In other CryoPort news, CFO Robert Stefanovich sold 135,036 shares of the company’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $14.80, for a total value of $1,998,532.80. Also, CEO Jerrell Shelton acquired 3,356 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was purchased at an average cost of $15.56 per share, for a total transaction of $52,219.36. Over the last three months, insiders have sold 150,036 shares of company stock valued at $2,224,533. 11.00% of the stock is currently owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. Coastal Investment Advisors Inc. acquired a new position in CryoPort during the 3rd quarter worth approximately $50,000. First Mercantile Trust Co. bought a new stake in shares of CryoPort during the third quarter worth $101,000. Handelsinvest Investeringsforvaltning acquired a new position in shares of CryoPort during the second quarter worth $183,000. Cadence Capital Management LLC acquired a new position in shares of CryoPort during the third quarter worth $211,000. Finally, SG Americas Securities LLC acquired a new position in shares of CryoPort during the second quarter worth $249,000. Hedge funds and other institutional investors own 71.59% of the company’s stock.
CryoPort Company Profile
CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.
Featured Article: What is the Ex-Dividend Date in Investing?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.